JThe following companies are expected to report earnings before the market opens on 03/15/2022. See our results calendar for a full list of expected results releases.

ANI Pharmaceuticals, Inc. (ANIP) releases its report for the quarter ending Dec. 31, 2021. The consensus earnings per share forecast for the biomedical company (gene) from the top analyst tracking the stock is $0.69. This value represents an increase of 6.15% compared to the same quarter last year. Zacks Investment Research reports that the 2021 price-to-earnings ratio for ANIP is 12.43 versus an industry ratio of -0.40, implying they will have higher earnings growth than their competitors in the same industry .

IDEAYA Biosciences, Inc. (IDYA) reports for the quarter ending December 31, 2021. The consensus earnings per share forecast for the biomedical company (gene) from the 7 analysts who track the stock is -$0.31. This value represents a decrease of 72.22% compared to the same quarter last year. The last two quarters, IDYA had negative earnings surprises; the last report they missed by -6.9%. The “days to cover” for this stock exceeds 12 days. Zacks Investment Research reports that the 2021 P/E ratio for IDYA is -10.41 versus an industry ratio of -0.40.

Citi Trends, Inc. (CTRN) reports for the quarter ending Jan. 31, 2022. The retail (shoes) company’s consensus earnings per share forecast from the top analyst tracking the stock is $1.09. This value represents a decrease of 39.78% compared to the same quarter last year. Over the past year, CTRN has exceeded expectations every quarter. The highest was in the 4th calendar quarter where they beat the consensus of 114.58%. Zacks Investment Research reports that the 2022 price-to-earnings ratio for CTRN is 4.86 versus an industry ratio of 12.10.

Altimmune, Inc. (ALT) reports for the quarter ending Dec. 31, 2021. The pharmaceutical company’s consensus earnings-per-share forecast from the 4 analysts who track the stock is -$0.64. This value represents a decrease of 276.47% compared to the same quarter last year. ALT missed consensus earnings per share in the 3rd calendar quarter of 2021 by -125%. Zacks Investment Research reports that the 2021 price-to-earnings ratio for ALT is -3.19 versus an industry ratio of -0.80.

Kamada Ltd. (KMDA) reports for the quarter ending December 31, 2021. The consensus earnings per share forecast for the biomedical company (gene) from the 1st analyst tracking the stock is -$0.01. This value represents a decrease of 125.00% compared to the same quarter last year. The “days to cover” for this stock exceeds 12 days. Zacks Investment Research reports that the 2021 P/E ratio for KMDA is 110.20 versus an industry ratio of -0.40, implying that they will have higher earnings growth than their competitors in the same industry.

Precision BioSciences, Inc. (DTIL) reports for the quarter ending December 31, 2021. The biomedical company (gene) consensus earnings per share forecast from 4 analysts who track the stock is -$0.48. This value represents a decrease of 9.09% compared to the same quarter last year. Over the past year, DTIL has exceeded expectations every quarter. The highest was in the 3rd calendar quarter where they beat consensus by 68.33%. Zacks Investment Research reports that the 2021 price-to-earnings ratio for DTIL is -6.11 versus an industry ratio of -0.40.

Kandi Technologies Group, Inc. (KNDI) reports for the quarter ending Dec. 31, 2021. The leading analyst’s earnings-per-share consensus forecast for the recreation (recreational) company is -$0.07. This value represents an increase of 65.00% compared to the same quarter last year. Zacks Investment Research reports that the 2021 P/E ratio for KNDI is -13.09 versus an industry ratio of 32.50.

Gamida Cell Ltd. (GMDA) reports for the quarter ending December 31, 2021. The biomedical company (gene) consensus earnings per share forecast from 3 analysts who track the stock is -$0.44. This value represents an increase of 35.29% compared to the same quarter last year. Zacks Investment Research reports that the 2021 price-to-earnings ratio for GMDA is -2.60 versus an industry ratio of -0.40.

Athens, Inc. (ATNX) reports for the quarter ending December 31, 2021. The biomedical company (gene) consensus earnings per share forecast from the 3 analysts who track the stock is -$0.04. This value represents an increase of 92.45% compared to the same quarter last year. ATNX missed consensus earnings per share in the 4th calendar quarter of 2020 by -26.19%. Zacks Investment Research reports that the 2021 P/E ratio for ATNX is -0.70 versus an industry ratio of -0.40.

Syros Pharmaceuticals, Inc. (SYRS) reports for the quarter ending December 31, 2021. The consensus earnings per share forecast for the biomedical company (gene) from the 4 analysts who track the stock is -$0.44. This value represents an increase of 27.87% compared to the same quarter last year. SYRS missed consensus earnings per share in the 4th calendar quarter of 2020 by -12.96%. The “days to cover” for this stock exceeds 10 days. Zacks Investment Research reports that the 2021 P/E ratio for SYRS is -0.77 versus an industry ratio of -0.40.

IMARA inc. (IMRA) releases a report for the quarter ending December 31, 2021. The consensus earnings per share forecast for the biomedical company (gene) from the 3 analysts who track the stock is -$0.79. This value represents an increase of 27.52% compared to the same quarter last year. IMRA missed consensus earnings per share in the 4th calendar quarter of 2020 by -29.76%. Zacks Investment Research reports that the 2021 price-to-earnings ratio for IMRA is -0.61 versus an industry ratio of -0.40.

Brickell Biotech, Inc. (BBI) reports for the quarter ending Dec. 31, 2021. The pharmaceutical company’s consensus earnings-per-share forecast from the 3 analysts who track the stock is -$0.09. This value represents an increase of 40.00% compared to the same quarter last year. Zacks Investment Research reports that the 2021 P/E ratio for BBI is -0.45 versus an industry ratio of -0.80, implying that they will have higher earnings growth than their competitors in the same industry.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.